Previous 10 | Next 10 |
Montrouge, France, June 2, 2021 DBV Technologies to Present at Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé...
Montrouge, France, May 19, 2021 DBV Technologies Announces Results of its 2021 Ordinary and Extraordinary General Meeting and the A ppointment of Dr. Adora Ndu , Pharm.D., J.D., and Dr. Ravi Madduri Rao, M.D., Ph.D., as Me mbers of its Board of ...
Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN C...
Montrouge, France, May 5, 2021 DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, tod...
BioLineRx (BLRX) +62% on positive top-line results from GENESIS phase 3 trial.Cocrystal Pharma (COCP) +40%.Huttig Building Products, Inc. (HBP) +26% on Q1 results.Vaxart (VXRT) +20% as its oral COVID-19 vaccine shows potential to offer promising solution against variants.Precip...
Montrouge, France, May 3, 2021 DBV Technologies Reports Q1 2021 Financial Results DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for th...
Montrouge, France, April 28, 2021 Ordinary and Extraordinary General Meeting of May 19 , 202 1 to be Held in Closed Virtual Session Due to COVID-19 Pandemic DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock ...
Gainers: [[PGNY]] +7.9%. [[XELB]] +7.0%. [[IDYA]] +6.9%. [[LSCC]] +6.6%. [[DKNG]] +6.0%.Losers: [[SPNE]] -3.8%. [[DBVT]] -3.4%. [[SYBX]] -3.0%. [[SESN]] -2.6%. [[DSEY]] -2.5%. For further details see: PGNY, XELB, SPNE and SYBX among after-hours movers
Gainers: Galectin Therapeutics (GALT) +17%, NexImmune (NEXI) +16%, Kymera Therapeutics (KYMR) +15%, Nurix Therapeutics (NRIX) +15%, DBV Technologies (DBVT) +13%.Losers: LifeMD (LFMD) -24%, CorMedix (CRMD) -11%, Cleveland BioLabs (CBLI) -9...
Montrouge, France, April 2, 2021 DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, announced today the provi...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutic...
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expecte...